The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. But this progress casts a puzzling shadow.
The drugs come at a high cost for relatively limited benefits, offering only a brief respite in the pace of cognitive decline. This reality raises a question: Are we fixated on such marginally effective treatments at the expense of more promising preventive measures?
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Kristi Storuschuk's webinar explores the relationship between fasting, exercise, and skeletal muscle adaptations, focusing on mitochondrial function.
Super Bowl commercial sells GLP-1s as the solution to our obesity epidemic.
The ongoing saga of allegations against a Montana oncologist for falsely diagnosing cancer and prescribing unnecessary treatments.
